dolastatin-10 has been researched along with Colorectal-Neoplasms* in 2 studies
1 trial(s) available for dolastatin-10 and Colorectal-Neoplasms
| Article | Year |
|---|---|
Phase II study of dolastatin-10 as first-line treatment for advanced colorectal cancer.
Dolastatin-10 is a potent inhibitor of microtubule assembly derived from the sea hare, which displayed significant antitumor activity in preclinical models. We conducted a phase II study of dolastatin-10 in patients with advanced colorectal cancer and no prior chemotherapy for metastatic disease. Fourteen patients received doses ranging from 300 microg/m(2) to 450 microg/m(2) as an intravenous push every 21 days. There were no major objective responses. Toxicity was mainly hematologic, with grade III or IV granulocytopenia occurring in 9 of 42 treatment courses. Other toxic effects were generally mild. Dolastatin-10 lacks clinically significant activity in advanced colorectal cancer when used in this dose and schedule. Topics: Aged; Antineoplastic Agents; Colorectal Neoplasms; Depsipeptides; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Oligopeptides | 2002 |
1 other study(ies) available for dolastatin-10 and Colorectal-Neoplasms
| Article | Year |
|---|---|
Isolation of dolastatin 10 from the marine cyanobacterium Symploca species VP642 and total stereochemistry and biological evaluation of its analogue symplostatin 1.
The potent antitumor agent dolastatin 10 (1) was originally isolated from the sea hare Dolabella auricularia, and we now report its isolation from the marine cyanobacterium Symploca sp. VP642 from Palau. The chemically related analogue symplostatin 1 (2) has been reisolated from Guamanian and Hawaiian varieties of S. hydnoides and its total stereochemistry completed by determining the N,N-dimethylisoleucine unit to be L. Symplostatin 1 (2), like dolastatin 10 (1), is a potent microtubule inhibitor. The antitumor activity of 2 was assessed in vivo against several murine tumors. Symplostatin 1 (2) was effective against a drug-insensitive mammary tumor and a drug-insensitive colon tumor; however, it was only slightly effective against two MDR tumors. Topics: Animals; Antineoplastic Agents; Aplysia; Chromatography, High Pressure Liquid; Colorectal Neoplasms; Cyanobacteria; Cytotoxins; Depsipeptides; Drug Resistance, Multiple; Female; Fibroblasts; Fluorescent Antibody Technique; Guam; Hawaii; Humans; Magnetic Resonance Spectroscopy; Mammary Neoplasms, Animal; Mice; Molecular Structure; Neoplasms; Oligopeptides; Palau; Pancreatic Neoplasms; Spectrometry, Mass, Fast Atom Bombardment; Spectrophotometry, Ultraviolet; Stereoisomerism; Tumor Cells, Cultured | 2001 |